Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights:
With the progress in biotechnology researchers were able to identify gamma delta T cells which have potential role in cancer immunosurveillance and have the potential to overcome the challenges in adoptive cell therapy. The cells have both innate and adaptive like properties, thus bridging between the adaptive and innate immunity. Furthermore, these subsets of cells produce different cytokines, chemokine and growth factors which help in generating immune response against the tumor cells.
Since their identification, gamma delta T cells are attractive candidates for the adoptive T cell therapy due to their unique biology and favorable characteristics in the management of cancer. The unique ability of targeting cells in major histocompatibility complex independent manner and recognizing a broader range of antigens has gained a lot of interest by the researchers. As of now, there are no approved gamma delta T therapies but a pool is present in clinical trials. Majority of the candidates belongs to early phase clinical trial which will require about 5-7 years to enter the market.
The encouraging response of the gamma delta T cell therapy in the management of cancer has surged the researchers for the exploiting the role of gamma delta T cells in other diseases also. A number of preclinical studies have been initiated by researchers to identify their role in diabetes, infectious and autoimmune diseases. As per report, it is expected that global gamma T cell therapy will witness huge growth rate in coming years and the market will be flourished with various potential candidates in management of wide range of diseases.
Despite several restraining factors in the growth of market including low physical frequency, high cost of development and stringent regulatory guidelines the overall market will follow a trajectory path. This is mainly due to the rising partnerships and collaborations among the pharmaceutical companies which increases the investment to carry out research and development activities. The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.
In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the exploitation of the therapy in management of other diseases will also propel the growth of marker. In addition to this, it is analyzed that North America will hold the top position in the global market due to rising geriatric population and increase government initiatives to promote novel therapies. In the forecast period, Europe and Asia-Pacific will also emerge as a potential market due to increase in awareness among the population of the region.
“Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights:
- Commercialization Market Potential After Market Launch: > USD 4 Billion
- Insight on Key Drugs In Research & Development
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
- Adopted Approaches for Gamma Delta T Cell Therapy
With the progress in biotechnology researchers were able to identify gamma delta T cells which have potential role in cancer immunosurveillance and have the potential to overcome the challenges in adoptive cell therapy. The cells have both innate and adaptive like properties, thus bridging between the adaptive and innate immunity. Furthermore, these subsets of cells produce different cytokines, chemokine and growth factors which help in generating immune response against the tumor cells.
Since their identification, gamma delta T cells are attractive candidates for the adoptive T cell therapy due to their unique biology and favorable characteristics in the management of cancer. The unique ability of targeting cells in major histocompatibility complex independent manner and recognizing a broader range of antigens has gained a lot of interest by the researchers. As of now, there are no approved gamma delta T therapies but a pool is present in clinical trials. Majority of the candidates belongs to early phase clinical trial which will require about 5-7 years to enter the market.
The encouraging response of the gamma delta T cell therapy in the management of cancer has surged the researchers for the exploiting the role of gamma delta T cells in other diseases also. A number of preclinical studies have been initiated by researchers to identify their role in diabetes, infectious and autoimmune diseases. As per report, it is expected that global gamma T cell therapy will witness huge growth rate in coming years and the market will be flourished with various potential candidates in management of wide range of diseases.
Despite several restraining factors in the growth of market including low physical frequency, high cost of development and stringent regulatory guidelines the overall market will follow a trajectory path. This is mainly due to the rising partnerships and collaborations among the pharmaceutical companies which increases the investment to carry out research and development activities. The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.
In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the exploitation of the therapy in management of other diseases will also propel the growth of marker. In addition to this, it is analyzed that North America will hold the top position in the global market due to rising geriatric population and increase government initiatives to promote novel therapies. In the forecast period, Europe and Asia-Pacific will also emerge as a potential market due to increase in awareness among the population of the region.
1. INTRODUCTION TO GAMMA DELTA T CELL THERAPY
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview to Gamma Delta T Cell Therapy
2. GAMMA DELTA T CELL THERAPY VS. CONVENTIONAL THERAPIES
2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
2.5 Gamma Delta T Cell Therapy Vs. Others
3. ROLE OF GAMMA DELTA T CELLS IN CANCER
3.1 Gamma Delta T Cells in Cancer Progression
3.2 Anti Tumor Activity of Gamma Delta T Cells
4. ADOPTED APPROACHES FOR GAMMA DELTA T CELL THERAPY
4.1 Gamma Delta T Cell as Bispecific Antibodies
4.2 CAR Gamma Delta T Cells
5. GAMMA DELTA T CELL THERAPY: KEY DRUGS IN RESEARCH & DEVELOPMENT
5.1 ADI-001
5.2 LAVA-051
5.3 INB-200
5.4 TCB002
5.5 INB-100
5.6 ACE1831
5.7 GDX012
6. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL PIPELINE OVERVIEW
6.1 By Country
6.2 By Company
6.3 By Indication
6.4 By Phase
7. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL TRIALS INSIGHT
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-II/III
8. GAMMA DELTA T CELL THERAPY IN LEUKEMIA
8.1 Role of Gamma Delta T Cells in Leukemia
8.2 Ongoing Clinical Research in Acute Leukemia
8.3 Clinical Trials in Chronic Lymphocytic Leukemia
8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia
9. GAMMA DELTA T CELL THERAPY IN LUNG CANCER
9.1 Overview
9.2 Ongoing Research & Development
9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer
10. GAMMA DELTA T CELLS IN BREAST CANCER
10.1 Overview
10.2 Ongoing Research & Development in Breast Cancer
10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer
11. GAMMA DELTA T CELLS IN COLORECTAL CANCER
11.1 Function of Gamma Delta T Cells in Colorectal Cancer
11.2 Ongoing Clinical Trials in Colorectal Cancer
11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
12. GAMMA DELTA T CELLS IN PANCREATIC CANCER
12.1 Overview
12.2 Ongoing Research & Development in Pancreatic Cancer
12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer
13. Current Clinical Research in Other Cancers
13.1 ONGOING CLINICAL TRIALS IN NEUROBLASTOMA
13.2 Ongoing Clinical Trials in Glioblastoma
13.3 Ongoing Research & Development in Head & Neck Cancer
14. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW
14.1 Current Market Scenario
14.2 Market Potential of Gamma Delta T Cell Therapy Market
15. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS
15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
15.2 Gamma Delta T Cell Therapy Market: Challenges
16. GAMMA DELTA T CELL THERAPY FUTURE PROSPECTS
17. COMPETITIVE LANDSCAPE
17.1 Acepodia
17.2 Adaptate Therapeutics
17.3 Adicet
17.4 Cytomed Therapeutics
17.5 Gadeta
17.6 GammaDelta Therapeutics
17.7 IN8bio
17.8 Kiromic Biopharma
17.9 Lava Therapeutics
17.10 Takeda Pharmaceuticals
17.11 TC Biopharm
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview to Gamma Delta T Cell Therapy
2. GAMMA DELTA T CELL THERAPY VS. CONVENTIONAL THERAPIES
2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
2.5 Gamma Delta T Cell Therapy Vs. Others
3. ROLE OF GAMMA DELTA T CELLS IN CANCER
3.1 Gamma Delta T Cells in Cancer Progression
3.2 Anti Tumor Activity of Gamma Delta T Cells
4. ADOPTED APPROACHES FOR GAMMA DELTA T CELL THERAPY
4.1 Gamma Delta T Cell as Bispecific Antibodies
4.2 CAR Gamma Delta T Cells
5. GAMMA DELTA T CELL THERAPY: KEY DRUGS IN RESEARCH & DEVELOPMENT
5.1 ADI-001
5.2 LAVA-051
5.3 INB-200
5.4 TCB002
5.5 INB-100
5.6 ACE1831
5.7 GDX012
6. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL PIPELINE OVERVIEW
6.1 By Country
6.2 By Company
6.3 By Indication
6.4 By Phase
7. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL TRIALS INSIGHT
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-II/III
8. GAMMA DELTA T CELL THERAPY IN LEUKEMIA
8.1 Role of Gamma Delta T Cells in Leukemia
8.2 Ongoing Clinical Research in Acute Leukemia
8.3 Clinical Trials in Chronic Lymphocytic Leukemia
8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia
9. GAMMA DELTA T CELL THERAPY IN LUNG CANCER
9.1 Overview
9.2 Ongoing Research & Development
9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer
10. GAMMA DELTA T CELLS IN BREAST CANCER
10.1 Overview
10.2 Ongoing Research & Development in Breast Cancer
10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer
11. GAMMA DELTA T CELLS IN COLORECTAL CANCER
11.1 Function of Gamma Delta T Cells in Colorectal Cancer
11.2 Ongoing Clinical Trials in Colorectal Cancer
11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
12. GAMMA DELTA T CELLS IN PANCREATIC CANCER
12.1 Overview
12.2 Ongoing Research & Development in Pancreatic Cancer
12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer
13. Current Clinical Research in Other Cancers
13.1 ONGOING CLINICAL TRIALS IN NEUROBLASTOMA
13.2 Ongoing Clinical Trials in Glioblastoma
13.3 Ongoing Research & Development in Head & Neck Cancer
14. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW
14.1 Current Market Scenario
14.2 Market Potential of Gamma Delta T Cell Therapy Market
15. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS
15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
15.2 Gamma Delta T Cell Therapy Market: Challenges
16. GAMMA DELTA T CELL THERAPY FUTURE PROSPECTS
17. COMPETITIVE LANDSCAPE
17.1 Acepodia
17.2 Adaptate Therapeutics
17.3 Adicet
17.4 Cytomed Therapeutics
17.5 Gadeta
17.6 GammaDelta Therapeutics
17.7 IN8bio
17.8 Kiromic Biopharma
17.9 Lava Therapeutics
17.10 Takeda Pharmaceuticals
17.11 TC Biopharm
LIST OF FIGURES
Figure 1-1: History of T cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 2-1: Limitation of CAR T Cell Therapy
Figure 2-2: Limitations of TIL
Figure 2-3: Limitations of Monoclonal Antibodies
Figure 2-4: Drawback of Chemotherapeutic Drugs
Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 4-1: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
Figure 4-2: Functional Advantages of ?? T Cells for CAR T Cancer Therapy
Figure 4-3: CAR ?? T Cells – Mechanism of Action
Figure 5-1: ADI-001 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-2: DRI Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-3: Adoptive Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 6-1: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Country, 2021 till 2026
Figure 6-2: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Company, 2021 till 2026
Figure 6-3: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Indication, 2021 till 2026
Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase, 2021 till 2026
Figure 8-1: Global – Leukemia Incidences & Mortality (Million), 2020 & 2040
Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
Figure 8-3: Mechanism of Action of V?9/CD123 Bispecific Antibody
Figure 8-4: Global – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-5: US – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-6: Europe – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-7: China – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-8: Japan – Estimated Leukemia Cancer Cases, 2020-2026
Figure 9-1: Global – Lung Cancer Incidences & Mortality (Million), 2020 & 2040
Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer
Figure 9-3: Global – Estimated Lung Cancer Cases, 2020-2026
Figure 9-4: US – Estimated Lung Cancer Cases, 2020-2026
Figure 9-5: Europe – Estimated Lung Cancer Cases, 2020-2026
Figure 9-6: China – Estimated Lung Cancer Cases, 2020-2026
Figure 9-7: Japan – Estimated Lung Cancer Cases, 2020-2026
Figure 10-1: Global – Breast Cancer Incidences (Million), 2020 & 2040
Figure 10-2: Global – Breast Cancer Mortality (Million), 2020 & 2040
Figure 10-3: Global – Estimated Breast Cancer Cases, 2020-2026
Figure 10-4: US – Estimated Breast Cancer Cases, 2020-2026
Figure 10-5: Europe – Estimated Breast Cancer Cases, 2020-2026
Figure 10-6: China – Estimated Breast Cancer Cases, 2020-2026
Figure 10-7: Japan – Estimated Breast Cancer Cases, 2020-2026
Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 11-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
Figure 11-3: Global – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-4: US – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-5: Europe – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-6: China – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-7: Japan – Estimated Colorectal Cancer Cases, 2020-2026
Figure 12-1: Global – Pancreatic Cancer Incidences, 2020 & 2040
Figure 12-2: Global – Pancreatic Cancer Mortality, 2020 & 2040
Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 12-4: Global – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-5: US – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-6: Europe – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-7: China – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-8: Japan – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 14-1: Global - Cell Therapy Market (US$ Billion), 2020 - 2026
Figure 14-2: Global – Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-3: Global – Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-4: Global – Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-5: Global – Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-6: Global – Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-7: Global – Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-8: Global – Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-9: Global – Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-10: Global – Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-11: Global – Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 15-1: Global – Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
Figure 15-2: Gamma Delta T Cells Favorable Market Parameters
Figure 15-3: Stages of Drug Development
Figure 1-1: History of T cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 2-1: Limitation of CAR T Cell Therapy
Figure 2-2: Limitations of TIL
Figure 2-3: Limitations of Monoclonal Antibodies
Figure 2-4: Drawback of Chemotherapeutic Drugs
Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 4-1: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
Figure 4-2: Functional Advantages of ?? T Cells for CAR T Cancer Therapy
Figure 4-3: CAR ?? T Cells – Mechanism of Action
Figure 5-1: ADI-001 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-2: DRI Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-3: Adoptive Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 6-1: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Country, 2021 till 2026
Figure 6-2: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Company, 2021 till 2026
Figure 6-3: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Indication, 2021 till 2026
Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase, 2021 till 2026
Figure 8-1: Global – Leukemia Incidences & Mortality (Million), 2020 & 2040
Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
Figure 8-3: Mechanism of Action of V?9/CD123 Bispecific Antibody
Figure 8-4: Global – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-5: US – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-6: Europe – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-7: China – Estimated Leukemia Cancer Cases, 2020-2026
Figure 8-8: Japan – Estimated Leukemia Cancer Cases, 2020-2026
Figure 9-1: Global – Lung Cancer Incidences & Mortality (Million), 2020 & 2040
Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer
Figure 9-3: Global – Estimated Lung Cancer Cases, 2020-2026
Figure 9-4: US – Estimated Lung Cancer Cases, 2020-2026
Figure 9-5: Europe – Estimated Lung Cancer Cases, 2020-2026
Figure 9-6: China – Estimated Lung Cancer Cases, 2020-2026
Figure 9-7: Japan – Estimated Lung Cancer Cases, 2020-2026
Figure 10-1: Global – Breast Cancer Incidences (Million), 2020 & 2040
Figure 10-2: Global – Breast Cancer Mortality (Million), 2020 & 2040
Figure 10-3: Global – Estimated Breast Cancer Cases, 2020-2026
Figure 10-4: US – Estimated Breast Cancer Cases, 2020-2026
Figure 10-5: Europe – Estimated Breast Cancer Cases, 2020-2026
Figure 10-6: China – Estimated Breast Cancer Cases, 2020-2026
Figure 10-7: Japan – Estimated Breast Cancer Cases, 2020-2026
Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 11-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
Figure 11-3: Global – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-4: US – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-5: Europe – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-6: China – Estimated Colorectal Cancer Cases, 2020-2026
Figure 11-7: Japan – Estimated Colorectal Cancer Cases, 2020-2026
Figure 12-1: Global – Pancreatic Cancer Incidences, 2020 & 2040
Figure 12-2: Global – Pancreatic Cancer Mortality, 2020 & 2040
Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 12-4: Global – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-5: US – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-6: Europe – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-7: China – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 12-8: Japan – Estimated Pancreatic Cancer Cases, 2020-2026
Figure 14-1: Global - Cell Therapy Market (US$ Billion), 2020 - 2026
Figure 14-2: Global – Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-3: Global – Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-4: Global – Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-5: Global – Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-6: Global – Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-7: Global – Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-8: Global – Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-9: Global – Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-10: Global – Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 14-11: Global – Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2021-2026
Figure 15-1: Global – Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
Figure 15-2: Gamma Delta T Cells Favorable Market Parameters
Figure 15-3: Stages of Drug Development
LIST OF TABLES
Table 6-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 7-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 8-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 9-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 10-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 6-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 6-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
Table 7-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 7-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
Table 8-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 8-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
Table 9-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 9-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
Table 10-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Table 10-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
